Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Nanoparticle Tracking Analysis

By Drug Discovery Trends Editor | February 22, 2010

UK biotechnology company, Henderson Morley plc, is using nanoparticle tracking analysis (NTA) from NanoSight to quantify virus particle number for batch to batch control.

Henderson Morley is developing anti-viral drugs and vaccines and biological products to fight a wide range of diseases in humans and animals. Their lead vaccine technology platform uses PREPS and L-particles, which are virus-like particles derived from Human Herpes Virus 1 (HHV-1). These particles have the same size as herpes viruses, but do not contain viral DNA and are therefore sterile. Conventional viral quantification relies on the infectious yield of viruses but as these particles do not replicate, an alternate quantification technique had to be found.

Previously the only way to quantify particle number relied on less accurate protein concentration measurements. The company had also used costly and time consuming electron microscopy through a local university, and although this gave good results, it was not practical for batch to batch quantification of the L and PREPS particles.

Several benefits have been produced since the purchase the NanoSight system. Henderson Morley’s Principal Scientist, Dr Chris Hartley says,  “The reproducibility of results providing both particle size and particle counts in real time has been excellent. Also negligible on-going and running costs have meant that the NanoSight instrument is proving to be a very cost effective solution.”

NanoSight 


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE